Rongchang Biopharmaceutical (Yantai) Co., Ltd. 2025 First Quarter Report

SZSIjust now · Announcements

Express News | RemeGen - Qtrly Operating Revenue RMB526 Mln

Reuters07:21 ET

REMEGEN: 2025 FIRST QUARTERLY REPORT

HKEX07:20 ET · Announcements

Zhitong Hong Kong stock short position statistics | April 28

Zhitong Hong Kong Stock Short Position Holding | April 28

Zhitong Finance06:30 ET

REMEGEN: 2024 ANNUAL REPORT

HKEX05:06 ET · Announcements

REMEGEN: Q1 revenue increased significantly by 59.17% to 0.526 billion yuan, and the net loss narrowed to 0.254 billion yuan.

Revenue has grown explosively, but the pressure on R&D remains heavy. REMEGEN's net loss for Q1 has narrowed to 0.254 billion yuan. Key highlights: Performance highlights: Q1 revenue reached 0.526 billion yuan, a significant year-on-year increase of 59.17%, mainly driven by a notable increase in sales of Taiatacept and Veldesilizumab. Loss reduction: Net loss is 0.254 billion yuan, which is an improvement compared to the net loss of 0.349 billion yuan in the same period last year; loss per share is 0.46 yuan, better than last year's 0.65 yuan. R&D investment: Q1 R&D expenses are 0.329 billion yuan, although the proportion of revenue has decreased to 62.53%, the absolute amount remains high. Cash situation: Net cash flow from operating activities.

wallstreetcn04:38 ET